Graft Versus Host Disease (GvHD) Treatment Market : Global Industry Analysis 2016 - 2025 and Opportunity Assessment 2026 - 2036

Future Market Insights

Graft Versus Host Disease (GvHD) Treatment Market

Key Insight

Graft versus host disease (GvHD) treatment sales will grow through 2036, led by monoclonal antibodies at a 34.0% share as the leading product segment. The market value stood at USD 3.1 billion in 2025 and is forecast to reach USD 5.9 billion by 2036 across key growth regions including Brazil and India.

June 18, 2026

Anurag Sharma

311 Pages

Cite this Report

Graft Versus Host Disease (GvHD) Treatment Market

https://www.futuremarketinsights.com/reports/graft-versus-host-disease-gvhd-treatment-market

License

Buy Now

Summary ToC Companies

Key Players

Abbott
Astellas Pharma Inc
Equillium
Incyte Corporation
Mallinckrodt Pharmaceuticals
Merck KGaA
Mesoblast Ltd
Neovii Biotech GmbH
Novartis
The Vanguard Group
L'Oréal
Soligenix
Takeda Pharmaceutical Company Limited

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Graft Versus Host Disease (GvHD) Treatment Market

Key Players

Similar Industry Reports